| __timestamp | Halozyme Therapeutics, Inc. | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 675200000 |
| Thursday, January 1, 2015 | 40028000 | 771800000 |
| Friday, January 1, 2016 | 45853000 | 1205500000 |
| Sunday, January 1, 2017 | 53816000 | 1146500000 |
| Monday, January 1, 2018 | 60804000 | 1125800000 |
| Tuesday, January 1, 2019 | 77252000 | 1166100000 |
| Wednesday, January 1, 2020 | 45736000 | 1175500000 |
| Friday, January 1, 2021 | 50323000 | 1111400000 |
| Saturday, January 1, 2022 | 143526000 | 1210100000 |
| Sunday, January 1, 2023 | 149182000 | 1274600000 |
| Monday, January 1, 2024 | 154335000 |
Data in motion
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Halozyme Therapeutics, Inc. and Perrigo Company plc have taken different paths in optimizing these costs. From 2014 to 2023, Halozyme's SG&A expenses grew by approximately 315%, peaking in 2023. In contrast, Perrigo's expenses increased by about 89% over the same period, with a steady rise each year.
Halozyme's significant jump in 2022 and 2023 suggests strategic investments or expansions, while Perrigo's consistent growth indicates a stable approach to cost management. This comparison highlights the diverse strategies companies employ to balance growth and efficiency. As investors and analysts look for insights, understanding these trends can provide a competitive edge in evaluating company performance.
Breaking Down SG&A Expenses: Bristol-Myers Squibb Company vs Perrigo Company plc
Comparing SG&A Expenses: Gilead Sciences, Inc. vs Perrigo Company plc Trends and Insights
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Halozyme Therapeutics, Inc.
Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Halozyme Therapeutics, Inc. Trends and Insights
Exelixis, Inc. and Perrigo Company plc: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. vs Mesoblast Limited: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Opthea Limited or Perrigo Company plc
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Perrigo Company plc
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Perrigo Company plc
Perrigo Company plc or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?
Perrigo Company plc vs MorphoSys AG: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Perrigo Company plc and Viridian Therapeutics, Inc.